Bacil Pharma Limited has informed BSE Limited that it did not enter into any related party transactions during the quarter/half year ended March 31, 2026. The disclosure was filed pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the related party transaction details have accordingly been submitted as "Nil" for the said period.

Regulatory Filing Details

The company submitted the disclosure to the Listing Compliance Department of BSE Limited on May 22, 2026. The filing was made in the prescribed format as required under the applicable SEBI Circular. Key details of the filing are summarised below:

Signatory Information

The disclosure was digitally signed and submitted by Ms. Chaitali Kalpataru Shah, who serves as Director & Chief Financial Officer of Bacil Pharma Limited, bearing DIN: 11167778. The filing was made from the company's registered office located at G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai – 400099.

The submission confirms the company's compliance with its periodic disclosure obligations under SEBI's listing regulations for the relevant reporting period.

bacil pharma has reported a net loss of ₹61.88 lakh for the financial year ended March 31, 2026, a significant increase from the net loss of ₹6.17 lakh recorded in the previous fiscal year. The company's revenue from operations remained at nil for the year, compared to ₹198.50 lakh in the corresponding period of the previous year. Total revenue for the fiscal year was driven entirely by other income, which amounted to ₹123.52 lakh.

Financial Performance

Total expenses for the year decreased to ₹24.50 lakh, down from ₹204.68 lakh in the previous year, primarily due to the absence of purchases of stock in trade and material consumption costs. Other expenses were reported at ₹19.61 lakh, while employee benefits expense stood at ₹4.89 lakh. The Board of Directors approved the audited financial results at its meeting held on May 22, 2026.

Quarterly Breakdown

For the quarter ended March 31, 2026, the company reported a net loss of ₹164.14 lakh. This loss was largely impacted by a loss of ₹226.30 lakh recognized on the fair valuation of financial assets under Other Comprehensive Income (OCI). In the preceding quarter ended December 31, 2025, the company had posted a profit of ₹6.10 lakh.

Balance Sheet and Cash Flows

As of March 31, 2026, the company's total assets stood at ₹2739.26 lakh, a slight increase from ₹2560.02 lakh in the previous year. Investments constituted a major portion of non-current assets, valued at ₹2424 lakh. Cash and cash equivalents decreased significantly to ₹56.85 lakh from ₹285.73 lakh at the end of the previous year. The cash flow statement indicates a net decrease in cash and cash equivalents of ₹228.88 lakh during the year.

Key Financial Metrics

The statutory auditors, M/s. Sarang Shivajirao Chavan and Associates, have issued an unmodified opinion on the financial results.